Evommune's EVO756 Phase 2b fails in atopic dermatitis; AD program halted

Evommune, Inc.

Phase 2b trial of EVO756 in 121 adults with moderate-to-severe AD missed primary and secondary endpoints at all doses.
Company will cease EVO756 development for AD; will continue evaluation in migraine prophylaxis.
EVO301 (IL-18BP fusion protein) becomes lead AD program; Phase 2b planned for mid-2027 after positive Phase 2a data.
Cash, equivalents, and investments expected to fund operations into 2029.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.